IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
Patients with Philadelphia-positive leukemia with Y253H or F359V mutation have a high risk of developing new mutations in the setting of dasatinib resistance
Jiang, Qian; Qin, Ya-Zhen; Lai, Yue-Yun; Jiang, Hao; Wang, Jing; Huang, Xiao-Jun
关键词BCR-ABL mutation chronic myeloid leukemia dasatinib nilotinib imatinib
刊名LEUKEMIA & LYMPHOMA
2015-07-01
DOI10.3109/10428194.2014.982639
56期:7页:2075-2081
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology ; Hematology
研究领域[WOS]Oncology ; Hematology
关键词[WOS]CHRONIC MYELOID-LEUKEMIA ; ABL KINASE DOMAIN ; CHRONIC MYELOGENOUS LEUKEMIA ; ACUTE LYMPHOBLASTIC-LEUKEMIA ; NILOTINIB FORMERLY AMN107 ; GIMEMA WORKING PARTY ; IMATINIB-RESISTANT ; CHRONIC-PHASE ; ACCELERATED-PHASE ; BLAST CRISIS
英文摘要

The treatment outcome and development of new mutations in patients with imatinib- and/or nilotinib-failure Philadelphia chromosome positive (Ph+) leukemia with highly nilotinib-resistant mutations (Y253H, E255K/V and F359V/C) were assessed on dasatinib therapy. A total of 111 patients with Ph+ leukemia were grouped into three cohorts by baseline BCR-ABL kinase domain mutation status: no mutation (n = 44), non-nilotinib-resistant mutations (n = 26) or nilotinib-resistant mutations (n = 41). The frequencies of hematological, cytogenetic and molecular responses and clinical resistance to dasatinib were similar among the three cohorts during dasatinib therapy. In dasatinib-resistant patients, new mutations were most frequently observed in the cohort with nilotinib-resistant mutations (p = 0.001). Multivariate analysis revealed that advanced disease and harboring Y253H or F359V mutation before dasatinib were independent predictors of developing new mutations. We conclude that patients with Ph+ leukemia with Y253H or F359V mutation have a high likelihood of developing new mutations in the setting of dasatinib resistance.

语种英语
WOS记录号WOS:000359888700025
项目编号Z131100004013026
资助机构Beijing Municipal Science &amp ; Technology Commission
引用统计
被引频次:1[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/58495
专题北京大学第二临床医学院_血液科
作者单位Peking Univ, Inst Hematol, Peoples Hosp, Beijing 100044, Peoples R China
推荐引用方式
GB/T 7714
Jiang, Qian,Qin, Ya-Zhen,Lai, Yue-Yun,et al. Patients with Philadelphia-positive leukemia with Y253H or F359V mutation have a high risk of developing new mutations in the setting of dasatinib resistance[J]. LEUKEMIA & LYMPHOMA,2015,56(7):2075-2081.
APA Jiang, Qian,Qin, Ya-Zhen,Lai, Yue-Yun,Jiang, Hao,Wang, Jing,&Huang, Xiao-Jun.(2015).Patients with Philadelphia-positive leukemia with Y253H or F359V mutation have a high risk of developing new mutations in the setting of dasatinib resistance.LEUKEMIA & LYMPHOMA,56(7),2075-2081.
MLA Jiang, Qian,et al."Patients with Philadelphia-positive leukemia with Y253H or F359V mutation have a high risk of developing new mutations in the setting of dasatinib resistance".LEUKEMIA & LYMPHOMA 56.7(2015):2075-2081.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Jiang, Qian]的文章
[Qin, Ya-Zhen]的文章
[Lai, Yue-Yun]的文章
百度学术
百度学术中相似的文章
[Jiang, Qian]的文章
[Qin, Ya-Zhen]的文章
[Lai, Yue-Yun]的文章
必应学术
必应学术中相似的文章
[Jiang, Qian]的文章
[Qin, Ya-Zhen]的文章
[Lai, Yue-Yun]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。